Market Closed -
Nasdaq
04:00:00 2025-02-13 pm EST
5-day change
1st Jan Change
31.92 USD
+4.54%
-5.03%
-23.23%
RBC Capital Adjusts Price Target on Moderna to $40 From $50
January 13, 2025 at 12:04 pm EST
Pending US vaccine decisions as Kennedy takes top health job
Feb. 13
RE
RFK Jr. Confirmed as HHS Head by Senate, Bloomberg Reports
Feb. 13
MT
RFK Jr. Confirmed as HHS Head by Senate
Feb. 13
MT
Inflation Wave Crashes Over Unprepared Wall Street
Feb. 12
Analysts recommendations: Gsk, Halma, Bellway, On Holding, Moderna…
Feb. 12
Analysts recommendations: Lyft, Coty, Upstart, On Holding, Moderna...
Feb. 12
BofA Securities Cuts Moderna Price Target to $34 From $41, Maintains Underperform Rating
Feb. 11
MT
Equities Move up as Markets Track Tariff News, Await Inflation Data
Feb. 10
MT
Equities Move up as Markets Track Tariff News, Await Inflation Data
Feb. 10
MT
Equities Rise Intraday as Markets Track Tariff News, Await Inflation Data
Feb. 10
MT
S&P 500 Companies' Quarterly Results Have Topped Growth Views so Far, Oppenheimer Says
Feb. 10
MT
Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.
Feb. 04
DJ
Wall Street: digesting the shock of the 'tariffs', Tesla falls 5%.
Feb. 03
CF
Moderna Shares Fall After TD Cowen Cuts Price Target
Jan. 29
MT
TD Cowen Adjusts Price Target on Moderna to $35 From $55, Keeps Hold Rating
Jan. 29
MT
Is Wall Street Ready to Move Past DeepSeek?
Jan. 29
Analyst recommendations: Mondi, Admiral, Severn Trent, Coinbase, Verizon, Moderna…
Jan. 29
Analyst recommendations: At&T, Caterpillar, Coinbase, Verizon, Moderna…
Jan. 29
Goldman Sachs Downgrades Moderna to Neutral From Buy, Adjusts Price Target to $51 From $99
Jan. 29
MT
Evercore ISI Adjusts Moderna Price Target to $50 From $60, Maintains In Line Rating
Jan. 27
MT
Goldman Sachs Adjusts Price Target on Moderna to $99 From $112, Keeps Buy Rating
Jan. 27
MT
JPMorgan Adjusts Price Target on Moderna to $40 From $45, Maintains Underweight Rating
Jan. 27
MT
Health Care Up on Novo Nordisk Optimism -- Health Care Roundup
Jan. 24
DJ
S&P 500 Posts Weekly Gain Amid Earnings Beats, Start of Trump Presidency
Jan. 24
MT
Sector Update: Health Care Stocks Decline Premarket Friday
Jan. 24
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
MRNA: Dynamic Chart
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (97.4%);
- grant revenue (1.4%);
- revenue from collaboration agreements (1.2%).
At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development.
Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).
More about the company
Last Close Price
31.92 USD
Average target price
62.01 USD
Spread / Average Target
+94.25%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1